On April 14, 2016 Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, reported the Company, in partnership with its collaborators, will present clinical and pre-clinical data from multiple product candidates at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 in New Orleans, Louisiana from April 16-20 (Press release, Juno, APR 14, 2016, View Source;p=RssLanding&cat=news&id=2157199 [SID:1234510814]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
There will be two presentations with clinical updates. On April 18th, Dr. Terry Fry will present the pre-clinical and clinical rationale as well as updated data from the ongoing Phase I trial of JCAR018, a chimeric antigen receptor (CAR) T cell product candidate targeting CD22, in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL). On April 20th, Dr. Phil Greenberg will present the pre-clinical rationale as well as the first clinical data in patients with solid organ tumors for JTCR016, a T cell receptor (TCR) cell product candidate targeting Wilms tumor-1 (WT-1).
Dr. Hy Levitsky, Juno’s Executive Vice President, Research and Chief Scientific Officer, will discuss pre-clinical data that informed the rationale and design of the ongoing Phase 1 trial for JCAR024, a CAR T cell product candidate targeting ROR-1, in ROR-expressing tumors. Additionally, two Juno-sponsored posters will be presented and Juno’s investigational CAR T cell product candidates will be featured in three additional presentations.
Clinical and Pre-Clinical Updates
CD22 CAR Update and Novel Mechanisms of Leukemic Resistance
Presenter: Terry J. Fry, M.D., Investigator, Pediatric Oncology Branch and Head of Hematologic Malignancies Section, National Cancer Institute, National Institutes of Health
Date: Monday, April 18, 2016: 12:35 – 12:58 p.m. Eastern Time
Location: Room 243
Targeting Cancer with Engineered T Cells
Presenter: Phil Greenberg, M.D., Head of Program in Immunology at the Fred Hutchinson Cancer Research Center and Professor, Medicine/Oncology and Immunology, University of Washington
Date: Wednesday, April 20, 2016: 10:55 – 11:20 a.m. Eastern Time
Location: New Orleans Theater B
Pre-Clinical Updates
ROR1 Targeted by CAR T Cells
Presenter: Hy Levitsky, M.D., Juno’s Executive Vice President, Research and Chief Scientific Officer
Date: Tuesday, April 19, 2016: 1:05 – 1:30 p.m. Eastern Time
Location: New Orleans Theater C
Toxicity and Efficacy Probability Intervals Design for Phase I Dose-Finding in Oncology Trials
Authors: Daniel Li, Ph.D., et al., Juno Department of Clinical Statistics
Date: Sunday, April 17, 2016: 1:00 – 5:00 p.m. Eastern Time
Location: Section 20, Poster Board #29
Comprehensive TIL Profiling by Simultaneous DNA Barcoding of Proteins, RNA and Natively Paired Immune Receptors from Millions of Single Cells
Authors: Katherine Connor, Ph.D., et al., Juno Department of Research, Receptor Discovery
Date: Monday, April 18, 2016: 8:00 a.m. – 12:00 p.m. Eastern Time
Location: Section 24, Poster Board #3
Educational and Major Symposia Sessions
The New T Cell Engineering Arsenal: CARs, CCRs, iCARs, and More
Presenter: Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory; Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center
Date: Saturday, April 16, 2016: 2:00 – 2:25 p.m. Eastern Time
Location: New Orleans Theater A
Novel Designs and Targets for CAR T Cells
Presenter: Stan Riddell, M.D., Member, Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Professor of Oncology, University of Washington School of Medicine
Date: Tuesday, April 19, 2016: 10:40 – 11:05 a.m. Eastern Time
Location: La Nouvelle Orleans Ballroom
Turbo Charged CAR T Cells
Presenter: Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory; Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center
Date: Tuesday, April 19, 2016: 11:40 a.m. – 12:05 p.m. Eastern Time
Location: La Nouvelle Orleans Ballroom
About Juno’s Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) Technologies
Juno’s CAR and TCR technologies genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. JCAR018, JTCR016, and JCAR024 are investigational product candidates and their safety and efficacy have not been established.